ClinicalTrials.gov
public full text
Public Domain
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.
This is a multicenter open-label mode of action study. Twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg Q4W subcutaneously. Main objectie is to investigate changes in inflammatory pathways induced by IL-23p19 blockade with guselkumab, in HS lesional skin. The total duration of the treatment period per subject is 16 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab#1111578
- A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis#910783
- Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran#889065
- An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain#882341
- Efficacy of Botulinum Toxin and Marjoram Oil Applications in Bruxism#1086771
Record · ID 994584
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive